CTI BioPharma Settles Investor Testing Info Row For $20M
Law360, New York (September 5, 2017, 5:25 PM EDT) -- CTI BioPharma Corp. and its executives will pay $20 million to a proposed class of investors for allegedly withholding information about patient deaths during clinical trials for a myelofibrosis drug, which led to a stock drop when the U.S. Food and Drug Administration stopped the trials, the investors told a Washington federal court on Friday.
The proposed class, led by DAFNA LifeScience LP, said in a motion for preliminary approval of the settlement and class certification that CTI has agreed to pay following talks with JAMS mediator Jed D. Melnick. The plaintiffs then requested a settlement hearing for Dec. 15....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!